ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » West Virginia » Cardiovascular Disease

Top Cardiovascular Disease Prescribers in West Virginia

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
PAUL ALAPPAT MD

Cardiovascular Disease

15,777

$1.05M

1034
875 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

30%
prescriptions for brand name drugs

Avg: 27%

$67
Average prescription price

Avg: $62

MAZEN NASHED M.D.

Cardiovascular Disease

14,144

$796K

314
211 are 65+

9%
patients receiving schedule two controlled substances

Avg: 0%

36%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 27%

$56
Average prescription price

Avg: $62

RICHARD TERRY MD

Cardiovascular Disease

13,831

$1.03M

772
687 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

35%
prescriptions for brand name drugs

Avg: 27%

$74
Average prescription price

Avg: $62

JOHN LOBBAN MD

Cardiovascular Disease

11,405

$934K

1088
940 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

31%
prescriptions for brand name drugs

Avg: 27%

$82
Average prescription price

Avg: $62

JASBIR MAKAR MD

Cardiovascular Disease

11,058

$346K

460
439 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

12%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

18%
prescriptions for brand name drugs

Avg: 27%

$31
Average prescription price

Avg: $62

MICHAEL OKEEFE MD

Cardiovascular Disease

10,005

$990K

829
725 are 65+

1%
patients receiving schedule two controlled substances

Avg: 0%

4%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

38%
prescriptions for brand name drugs

Avg: 27%

$99
Average prescription price

Avg: $62

SATHYANARAYAN REDDY M.D.

Cardiovascular Disease

9,661

$569K

766
688 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

28%
prescriptions for brand name drugs

Avg: 27%

$59
Average prescription price

Avg: $62

MADHU DHARAWAT M.D.

Cardiovascular Disease

9,126

$558K

801
655 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 27%

$61
Average prescription price

Avg: $62

SHAHID RANA MD FACC

Cardiovascular Disease

9,049

$425K

591
412 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 27%

$47
Average prescription price

Avg: $62

ROBERT FANNING D.O.

Cardiovascular Disease

8,273

$399K

719
643 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 27%

$48
Average prescription price

Avg: $62

RALPH STEVENS MD

Cardiovascular Disease

7,917

$657K

390
313 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

7%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

27%
prescriptions for brand name drugs

Avg: 27%

$83
Average prescription price

Avg: $62

BASSAM MOUSHMOUSH MD

Cardiovascular Disease

7,829

$442K

585
326 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

30%
prescriptions for brand name drugs

Avg: 27%

$56
Average prescription price

Avg: $62

MUHAMMAD MIAN MD

Cardiovascular Disease

7,789

$488K

409
274 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

32%
prescriptions for brand name drugs

Avg: 27%

$63
Average prescription price

Avg: $62

SAYEED AHMED MD

Cardiovascular Disease

7,328

$332K

184
148 are 65+

7%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 27%

$45
Average prescription price

Avg: $62

DAVID CHURCH M.D.

Cardiovascular Disease

7,210

$323K

608
514 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 27%

$45
Average prescription price

Avg: $62

GERARDO LOPEZ M.D.

Cardiovascular Disease

7,111

$391K

516
444 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

27%
prescriptions for brand name drugs

Avg: 27%

$55
Average prescription price

Avg: $62

DAVID GNEGY

Cardiovascular Disease

6,812

$386K

547
468 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 27%

$57
Average prescription price

Avg: $62

JEBRAN KARAM MD

Cardiovascular Disease

6,759

$345K

582
482 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 27%

$51
Average prescription price

Avg: $62

HENRY MILLIT MD

Cardiovascular Disease

6,446

$171K

326
296 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

16%
prescriptions for brand name drugs

Avg: 27%

$27
Average prescription price

Avg: $62

MORGAN LYONS MD

Cardiovascular Disease

6,225

$631K

564
488 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

41%
prescriptions for brand name drugs

Avg: 27%

$101
Average prescription price

Avg: $62

EDWARD CHIU M.D.

Cardiovascular Disease

5,999

$182K

417
366 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

13%
prescriptions for brand name drugs

Avg: 27%

$30
Average prescription price

Avg: $62

ADEL FRENN M.D.

Cardiovascular Disease

5,809

$240K

542
485 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 27%

$41
Average prescription price

Avg: $62

JOHN WURTZBACHER M.D.

Cardiovascular Disease

5,792

$232K

474
414 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

21%
prescriptions for brand name drugs

Avg: 27%

$40
Average prescription price

Avg: $62

JOHN MCKNIGHT MD

Cardiovascular Disease

5,659

$438K

670
572 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

30%
prescriptions for brand name drugs

Avg: 27%

$77
Average prescription price

Avg: $62

STANLEY PAMFILIS

Cardiovascular Disease

5,418

$402K

496
417 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

28%
prescriptions for brand name drugs

Avg: 27%

$74
Average prescription price

Avg: $62

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank